Rationality evaluation of human albumin in the treatment of liver cirrhosis based on weighted TOPSIS method
- VernacularTitle:加权TOPSIS法评价人血白蛋白治疗肝硬化的合理性
- Author:
Lu LIU
1
;
Danwei ZHENG
1
;
Lejia XU
1
Author Information
1. Dept. of Pharmacy，Third Affiliated Hospital of Sun Yat-sen University，Guangzhou 510630，China
- Publication Type:Journal Article
- Keywords:
human albumin;
liver cirrhosis;
weighted TOPSIS method;
rational drug use
- From:
China Pharmacy
2022;33(23):2917-2920
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To establish the drug use evaluation criteria of human albumin （HA） in the treatment of liver cirrhosis based on weighted technique for order preference by similarity to ideal solution （TOPSIS） method， and to comprehensively evaluate the utilization of HA. METHODS The drug use evaluation criteria of HA was established with reference to guidelines of liver cirrhosis treatment at home and abroad and HA prescription evaluation method， based on the HA instructions. The weighted TOPSIS method was used to evaluate the rationality of HA drug use in inpatients with liver cirrhosis diagnosed by the infection department of our hospital in 2020. RESULTS The established drug use evaluation criteria for HA included 8 evaluation indicators， i.e. baseline examination， indication， contraindication， combined use of drugs， usage and dosage， and so on； the scoring weight was set by consulting experts. According to the evaluation of the closeness degree （Ci） between the HA drug use of 1 068 medical records and the optimal plan and the worst plan in our hospital， the result showed that 133 （12.45%） were evaluated as reasonable medical records （Ci≥0.8）， 576 （53.93%） as basically reasonable medical records （0.6≤Ci＜0.8）， and 359 （33.61%） as unreasonable medical records （Ci＜0.6）. The main unreasonable problems were the absence of baseline examination， non-indication medication， medication for contraindication， etc. CONCLUSIONS The drug use evaluation criteria of HA based on the weighted TOPSIS method can be used to evaluate the rational use of the drug. The drug use of HA in patients with liver cirrhosis in our hospital is reasonable， and we should continue to strengthen the management to reduce or avoid unreasonable drug use.
